Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.

Harrington K., Parkes E., Weiss J., Ingham M., Cervantes A., Calvo E., Klinkhardt U., Sikken P., Schmohl M., Garralda E.

Type

Conference paper

Publication Date

07/2021

Volume

81

Permalink